<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Maharaj AR</submitter><funding>NICHD NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>National Institute of Child Health and Human Development</funding><pagination>542-554</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9008710</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>87(2)</volume><pubmed_abstract>&lt;h4>Aims&lt;/h4>The aim of this study was to evaluate the population pharmacokinetics (PopPK) of olanzapine in children and devise a model-informed paediatric dosing scheme.&lt;h4>Methods&lt;/h4>The PopPK of olanzapine was characterized using opportunistically collected plasma samples from children receiving olanzapine per standard of care for any indication. A nonlinear mixed effect modelling approach was employed for model development using the software NONMEM (v7.4). Simulations from the developed PopPK model were used to devise a paediatric dosing scheme that targeted comparable plasma exposures to adolescents and adults.&lt;h4>Results&lt;/h4>Forty-five participants contributed 83 plasma samples towards the analysis. The median (range) postnatal age and body weight of participants were 3.8 years (0.2</pubmed_abstract><journal>British journal of clinical pharmacology</journal><pubmed_title>Population pharmacokinetics of olanzapine in children.</pubmed_title><pmcid>PMC9008710</pmcid><funding_grant_id>HHSN267200700051C</funding_grant_id><funding_grant_id>HHSN275201000003C</funding_grant_id><funding_grant_id>K23 HD090239</funding_grant_id><funding_grant_id>R01 HD097775</funding_grant_id><funding_grant_id>HHSN275201000003I</funding_grant_id><funding_grant_id>UL1 TR002369</funding_grant_id><funding_grant_id>KL2 TR001115</funding_grant_id><funding_grant_id>UL1 TR002538</funding_grant_id><funding_grant_id>K23 HD091398</funding_grant_id><pubmed_authors>Goldstein SL</pubmed_authors><pubmed_authors>Maharaj AR</pubmed_authors><pubmed_authors>Cohen-Wolkowiez M</pubmed_authors><pubmed_authors>Wu H</pubmed_authors><pubmed_authors>Al-Uzri A</pubmed_authors><pubmed_authors>Sherwin CMT</pubmed_authors><pubmed_authors>Payne EH</pubmed_authors><pubmed_authors>Zimmerman KO</pubmed_authors><pubmed_authors>Kalra R</pubmed_authors><pubmed_authors>Watt K</pubmed_authors><pubmed_authors>Erinjeri J</pubmed_authors><pubmed_authors>Hornik CP</pubmed_authors><pubmed_authors>Autmizguine J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Population pharmacokinetics of olanzapine in children.</name><description>&lt;h4>Aims&lt;/h4>The aim of this study was to evaluate the population pharmacokinetics (PopPK) of olanzapine in children and devise a model-informed paediatric dosing scheme.&lt;h4>Methods&lt;/h4>The PopPK of olanzapine was characterized using opportunistically collected plasma samples from children receiving olanzapine per standard of care for any indication. A nonlinear mixed effect modelling approach was employed for model development using the software NONMEM (v7.4). Simulations from the developed PopPK model were used to devise a paediatric dosing scheme that targeted comparable plasma exposures to adolescents and adults.&lt;h4>Results&lt;/h4>Forty-five participants contributed 83 plasma samples towards the analysis. The median (range) postnatal age and body weight of participants were 3.8 years (0.2</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2026-05-09T21:56:45.858Z</modification><creation>2025-04-04T13:30:52.622Z</creation></dates><accession>S-EPMC9008710</accession><cross_references><pubmed>32497307</pubmed><doi>10.1111/bcp.14414</doi></cross_references></HashMap>